Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (2169)	3/29/1999 8:09:00 AM
From: BMcV	Respond to of 10280

Lancet article -- if anyone hasn't been following the Yahoo discussion on this issue, here are the relevant messages: messages.yahoo.com@m2.yahoo.com messages.yahoo.com@m2.yahoo.com messages.yahoo.com@m2.yahoo.com messages.yahoo.com@m2.yahoo.com messages.yahoo.com@m2.yahoo.com I don't see this as much of an issue for SEPR. Lots of widely prescribed drugs, including Claritin, may be associated with cardiac side-effects in a very small number of patients. So can salt, sugar, and caffeine. Even in the worst case scenario, this would not invalidate SEPR's active metabolite methodology. SEPR scientists have identified to the satisfaction of the medical scientific community and, most importantly, to the scientists at the FDA, the mechanism by which Allegra circumvents the cardiac toxicity of Seldane. Otherwise, the FDA would never have pulled Seldane from the market. If there is a secondary causative factor involved, that is a separate issue, and one that is shared by other drugs in the class, like Claritin. The original article can be found (if you are a subscriber) at www.thelancet.com